Skip to main content
Log in

Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Twelve elderly non-insulin dependent diabetic patients took part in a double-blind, cross-over, randomized study comparing simvastatin 30 mg/day and placebo. Each treatment period lasted 3 weeks and was separated by a 3 week wash-out period. At the end of each treatment period all subjects underwent in randomized order an oral glucose tolerance test (OGTT; 75 g) and an euglycaemic hyperinsulinaemic (50 mU/kg·h) glucose clamp.

Simvastatin compared to placebo significantly reduced plasma total cholesterol (7.9 vs 5.3 mmol·l−1), LDL-cholesterol (7.2 vs 4.3 mmol·l−1), triglycerides (2.9 vs 2.1 mmol·l−1), free fatty acids (1106 vs 818 mmol−1) and glucose (7.4 vs 6.6 mmol·l−1) levels.

After simvastatin, and in the last 60 min of the glucose clamp, there was an improvement in the action of insulin as demonstrated by stronger inhibition of hepatic glucose output (2.7 vs 5.2 μmol·kg−1·min−1) and stimulation both of the glucose disappearance rate (26.3 vs 19.5 μmol·kg−1·min−1) and glucose metabolic clearance rate (4.3 vs 3.6 ml·kg−1·min−1).

The changes in glucose turnover parameters were significantly correlated with basal plasma free fatty acids and were independent of plasma glucoregulatory hormones. In conclusion, simvastatin seems to exert beneficial effects both on lipid and glucose metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kannel WB, Dawber TR, Kagon A, Revostikie N, Stokies J (1961) Factors of risk in the development of coronary heart disease: six years follow-up experience: the Framingham study. Ann Intern Med 55: 33–39

    Google Scholar 

  2. American Diabetes Association (1989) Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12: 573–579

    Google Scholar 

  3. Walker JF (1988) HMG-CoA reductase inhibitors. Current clinical experience. Drugs 36 [Suppl 3]: 83–86

    Google Scholar 

  4. Slater EE, MacDonald JS (1988) Mechanism of action and biological profile of HMG-CoA reductase inhibitors. A new therapeutic alternative. Drugs 36 [Suppl 3]: 77–82

    Google Scholar 

  5. Kobayashi M, Ishida F, Takahashi T, Tagucki K, Watanabe K, Ohmura I, Kamei T (1989) Preventive effect of MK-733 (simvastatin) on inhibitors of HMG-CoA reductase, on hypercholesterolaemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn J Pharmacol 49: 125–133

    Google Scholar 

  6. Saku K, Sasaki J, Arakawa K (1989) Low dose of simvastatin (MK-733) on serum lipids, lipoproteins and apolipoproteins in patients with hypocholesterolaemia. Clin Ther 11: 247–257

    Google Scholar 

  7. De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214–223

    Google Scholar 

  8. Paolisso G, Giugliano D, Scheen AJ, Franchimont P, D'Onofrio P, Lefebvre PJ (1987) Primary role of glucagon in the effect of Beta-endorphin on glucose homeostasis in normal men. Acta Endocrinol (Kbh) 195: 161–169

    Google Scholar 

  9. Prado M de, Zurcker G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within fentomole range. Life Sci 19: 1161–1167

    Google Scholar 

  10. Paolisso G, Sgambato S, Gentile S, Memoli P, Varricchio M, D'Onofrio F (1988) Adavantageous metabolic effects of pulsatile insulin delivery in non-insulin dependent diabetic subjects. J Clin Endocrinol Metabol 67: 1005–1010

    Google Scholar 

  11. Paolisso G, Scheen AJ, Luyckx AS, Lefebvre PJ (1987) Pulsatile hyperglucagonemia fails to increase hepatic glucose production in normal man. Am J Physiol 252: E1–7

    Google Scholar 

  12. Steele R (1959) Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420–430

    Google Scholar 

  13. Bagdade JD, Porte D Jr, Bierman EL (1967) Diabetic lipemia. A form of acquired fat-induced lipemia. N Engl J Med 276: 427–433

    Google Scholar 

  14. Brunzell JD, Porte D Jr, Bierman EL (1975) Reversible abnormalities in post-heparin lipolytic activity during the late phase of release in diabetes mellitus (post-heparin lypolitic activity in diabetes) Metabolism 24: 1123–1137

    Google Scholar 

  15. Fronzo RA de (1988) The triumvirate: b-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667–687

    Google Scholar 

  16. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595–1607

    Google Scholar 

  17. Garg A, Grundy SM (1988) Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. N Engl J Med 318: 81–86

    Google Scholar 

  18. Garg A, Grundy SM (1989) Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes 38: 364–372

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paolisso, G., Sgambato, S., De Riu, S. et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol 40, 27–31 (1991). https://doi.org/10.1007/BF00315135

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315135

Key words

Navigation